Book contents
- Frontmatter
- Contents
- Participants
- Declarations of personal interest
- Preface
- 1 Overview and definitions of polycystic ovary syndrome and the polycystic ovary
- 2 Genetics and pathogenesis of polycystic ovary syndrome
- 3 Ethnic variations in the expression of polycystic ovary syndrome
- 4 Quality of life for women with polycystic ovary syndrome
- 5 Insulin resistance, the metabolic syndrome and polycystic ovary syndrome
- 6 Management of polycystic ovary syndrome through puberty and adolescence
- 7 Long-term health risks of polycystic ovary syndrome
- 8 Approaches to lifestyle management in polycystic ovary syndrome
- 9 Management of obesity in polycystic ovary syndrome, including anti-obesity drugs and bariatric surgery
- 10 Definition of hyperandrogenism
- 11 Treatment of hyperandrogenism in polycystic ovary syndrome
- 12 Choices in the treatment of anovulatory polycystic ovary syndrome
- 13 Predictors of ovarian response to ovarian stimulation: progress towards individualised treatment in ovulation induction
- 14 Surgical management of anovulatory infertility in polycystic ovary syndrome
- 15 The role of insulin-sensitising drugs in the treatment of polycystic ovary syndrome
- 16 The role of in vitro maturation of oocytes for anovulatory polycystic ovary syndrome
- 17 Acupuncture and/or herbal therapy as an alternative or complement for relief of polycystic ovary syndrome-related symptoms
- 18 Consensus views arising from the 59th Study Group: Current Management of Polycystic Ovary Syndrome
- Index
1 - Overview and definitions of polycystic ovary syndrome and the polycystic ovary
Published online by Cambridge University Press: 05 July 2014
- Frontmatter
- Contents
- Participants
- Declarations of personal interest
- Preface
- 1 Overview and definitions of polycystic ovary syndrome and the polycystic ovary
- 2 Genetics and pathogenesis of polycystic ovary syndrome
- 3 Ethnic variations in the expression of polycystic ovary syndrome
- 4 Quality of life for women with polycystic ovary syndrome
- 5 Insulin resistance, the metabolic syndrome and polycystic ovary syndrome
- 6 Management of polycystic ovary syndrome through puberty and adolescence
- 7 Long-term health risks of polycystic ovary syndrome
- 8 Approaches to lifestyle management in polycystic ovary syndrome
- 9 Management of obesity in polycystic ovary syndrome, including anti-obesity drugs and bariatric surgery
- 10 Definition of hyperandrogenism
- 11 Treatment of hyperandrogenism in polycystic ovary syndrome
- 12 Choices in the treatment of anovulatory polycystic ovary syndrome
- 13 Predictors of ovarian response to ovarian stimulation: progress towards individualised treatment in ovulation induction
- 14 Surgical management of anovulatory infertility in polycystic ovary syndrome
- 15 The role of insulin-sensitising drugs in the treatment of polycystic ovary syndrome
- 16 The role of in vitro maturation of oocytes for anovulatory polycystic ovary syndrome
- 17 Acupuncture and/or herbal therapy as an alternative or complement for relief of polycystic ovary syndrome-related symptoms
- 18 Consensus views arising from the 59th Study Group: Current Management of Polycystic Ovary Syndrome
- Index
Summary
Introduction
Polycystic ovary syndrome (PCOS) is a heterogeneous collection of signs and symptoms that, gathered together, form a spectrum of a disorder with a mild presentation in some but a severe disturbance of reproductive, endocrine and metabolic function in others. The pathophysiology of PCOS appears to be multifactorial and polygenic. The definition of the syndrome has been much debated, with key features including menstrual cycle disturbance, hyperandrogenism and obesity (see Box 1.1). There are many extra-ovarian aspects to the pathophysiology of PCOS but ovarian dysfunction is central.
The joint European Society of Human Reproduction and Embryology (ESHRE)/American Society for Reproductive Medicine (ASRM) consensus meeting in 2003 agreed a refined definition of PCOS, namely the presence of two of the following three criteria: (1) oligo-ovulation and/or anovulation, (2) hyperandrogenism (clinical and/or biochemical), (3) polycystic ovaries; with the exclusion of other causes of menstrual cycle disturbance or androgen excess (see Table 1.1).
The morphology of the polycystic ovary has been defined as an ovary with 12 or more follicles measuring 2-9 mm in diameter and/or an increased ovarian volume (more than 10 cm3).
There is considerable heterogeneity of symptoms and signs among women with PCOS and, for an individual, these may change over time. PCOS appears to be familial and various aspects of the syndrome may be differentially inherited. Polycystic ovaries can even exist without clinical signs of the syndrome, which may then become expressed over time.
Keywords
- Type
- Chapter
- Information
- Current Management of Polycystic Ovary Syndrome , pp. 1 - 12Publisher: Cambridge University PressPrint publication year: 2010